Forge Biologics

Forge Biologics

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $160M

Overview

Forge Biologics is a specialized gene therapy CDMO focused exclusively on AAV manufacturing, providing integrated services from molecular development to commercial production. The company differentiates itself through its proprietary FUEL™ technology platform, designed to increase AAV yield and quality, and its large-scale, dedicated cGMP facility, The Hearth. As a subsidiary of the Ajinomoto Group, Forge combines biotech agility with the resources of a global corporation, serving over 60 clients across more than 35 disease indications.

BiologicsViral Technology

Technology Platform

FUEL™ platform for AAV manufacturing, including Ignition Cells™, pEMBR™ 2.0 Ad Helper, modified rep/cap genes, and advanced analytics.

Funding History

2
Total raised:$160M
Series B$120M
Series A$40M

Opportunities

The rapid growth of the gene therapy pipeline, particularly using AAV vectors, creates massive demand for specialized, high-yield manufacturing capacity.
Forge's exclusive AAV focus and proprietary FUEL platform position it to capture significant market share as a preferred partner for biotechs and pharma companies.
Its large-scale cGMP facility allows it to compete for lucrative commercial-scale contracts as client therapies advance.

Risk Factors

Intense competition from both large, established CDMOs and other niche gene therapy manufacturers poses a constant threat.
The gene therapy sector is susceptible to clinical setbacks and regulatory hurdles, which could dampen overall demand for manufacturing services.
Technological obsolescence is a risk if new production systems surpass the yield or cost advantages of Forge's platform.

Competitive Landscape

Forge competes in the gene therapy CDMO space against large, multi-product giants like Lonza and Catalent, as well as specialized peers such as Oxford Biomedica, Vigene Biosciences, and Andelyn Biosciences. Its key differentiators are its exclusive AAV focus, proprietary yield-enhancing technology platform (FUEL), and the scale of its dedicated AAV facility (The Hearth), which is among the largest of its kind.